SLC22A2 Blocking Peptide (N-term)

Background:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.

Other Names:
Solute carrier family 22 member 2, Organic cation transporter 2, hOCT2, SLC22A2, OCT2

Target/Specificity:
The synthetic peptide sequence is selected from aa 77-89 of HUMAN SLC22A2

Gene Name: SLC22A2 (HGNC:10966)

Gene ID: 6582
Primary Accession: O15244
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.